Education
About Us
Working with TipRanks
Follow Us
RegenXBio Inc. (RGNX)
:RGNX
Top Page
RegenXBio
(NASDAQ:RGNX)
46Neutral
Positive Factors
Financial Performance
A strong cash position, bolstered by the Nippon Shinyaku partnership and expected milestone from AbbVie, positions RGNX for transition to a commercial gene therapy company.
Partnerships
Partnerships with companies like Nippon Shinyaku and AbbVie validate RGNX's ability to execute clinically and from a business development perspective.
Negative Factors
Market Perception
DMD program remains underappreciated by investors.
RegenXBio (RGNX) vs. S&P 500 (SPY)
Market Cap
$302.72M
Dividend YieldN/A
Average Volume (3M)794.04K
Price to Earnings (P/E)―
Beta (1Y)1.86
Revenue Growth-15.14%
EPS Growth15.84%
CountryUS
Employees344
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.03
Shares Outstanding49,545,070
10 Day Avg. Volume907,225
30 Day Avg. Volume794,041
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.92
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$26.88Price Target Upside310.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
RegenXBio Business Overview & Revenue Model
Company DescriptionREGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
How the Company Makes MoneyRegenXBio primarily generates revenue through licensing agreements and collaborations with other biotechnology and pharmaceutical companies. By licensing its NAV Technology Platform, the company receives upfront payments, milestone payments upon the achievement of specific development or regulatory milestones, and royalties on net sales of products developed using its platform. In addition to licensing fees, RegenXBio earns revenue from strategic partnerships that support the clinical development of its gene therapy candidates. The company's earnings are significantly influenced by the successful advancement of its internal pipeline through clinical phases, regulatory approvals, and subsequent commercialization of products.
RegenXBio Financial Statement Overview
Summary
RegenXBio's financial position reflects significant challenges, with declining revenue and profitability. The income statement shows major contractions in revenue and negative profit margins. The balance sheet demonstrates reasonable leverage but declining equity, and cash flow struggles highlight liquidity concerns.Income Statement
RegenXBio has faced a significant decline in revenue and profit margins over the years. The TTM Gross Profit Margin stands at 39.45%, while the Net Profit Margin is heavily negative at -283.16%, indicating challenges in profitability. The revenue has decreased from $470.35 million in 2021 to $84.33 million in TTM 2024, reflecting a substantial contraction, which suggests difficulties in sustaining growth.35
Negative
Balance Sheet
The company maintains a moderate debt-to-equity ratio of 0.28 in TTM 2024, suggesting reasonable leverage. However, the equity ratio has decreased to 58.06%, indicating a decline in equity as a proportion of total assets. Return on Equity is negative at -79.22%, highlighting profitability issues. Nevertheless, the balance sheet remains relatively stable with a decent equity base.60
Neutral
Cash Flow
RegenXBio's cash flow situation is challenging, with negative operating cash flow and free cash flow in TTM 2024. The Free Cash Flow to Net Income Ratio is 0.77, indicating some cash flow alignment with net income losses. The Free Cash Flow Growth Rate shows a slight improvement but remains negative, which could strain liquidity if trends persist.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 84.33M | 90.24M | 112.72M | 470.35M | 154.57M | 35.23M | Gross Profit |
| 33.27M | 53.03M | 58.18M | 418.51M | 118.85M | 26.99M | EBIT |
| -243.78M | -268.13M | -262.88M | 159.98M | -119.23M | -149.00M | EBITDA |
| -217.82M | -239.46M | -244.24M | 169.54M | -96.83M | -90.34M | Net Income Common Stockholders |
| -238.81M | -263.49M | -280.32M | 127.84M | -111.25M | -94.73M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 319.76M | 275.26M | 364.64M | 457.44M | 475.74M | 296.21M | Total Assets |
| 543.81M | 573.97M | 833.27M | 1.11B | 708.16M | 497.91M | Total Debt |
| 5.85M | 89.29M | 94.80M | 86.68M | 72.65M | 11.29M | Net Debt |
| -69.71M | 54.77M | -2.15M | -258.53M | -265.77M | -58.22M | Total Liabilities |
| 34.97M | 262.23M | 317.07M | 349.61M | 330.41M | 47.71M | Stockholders Equity |
| 508.85M | 311.74M | 516.20M | 764.30M | 377.75M | 450.20M |
| Cash Flow | Free Cash Flow | ||||
| -184.74M | -228.37M | -238.21M | 134.70M | -80.93M | -119.42M | Operating Cash Flow |
| -182.26M | -218.41M | -207.49M | 218.88M | -54.06M | -107.70M | Investing Cash Flow |
| 97.15M | 190.94M | -11.93M | -406.64M | 122.76M | 93.56M | Financing Cash Flow |
| 88.46M | -34.97M | -28.84M | 195.25M | 200.21M | 8.38M |
RegenXBio Technical Analysis
Negative
6.55
Price Trends
7.33
Negative
8.35
Negative
10.25
Negative
Market Momentum
-0.35
Negative
44.78
Neutral
68.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGNX, the sentiment is Negative. The current price of 6.55 is below the 20-day moving average (MA) of 6.70, below the 50-day MA of 7.33, and below the 200-day MA of 10.25, indicating a bearish trend. The MACD of -0.35 indicates Negative momentum. The RSI at 44.78 is Neutral, neither overbought nor oversold. The STOCH value of 68.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RGNX.
RegenXBio Risk Analysis
RegenXBio disclosed 50 risk factors in its most recent earnings report. RegenXBio reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RegenXBio Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $9.77B | 41.86 | 19.71% | ― | 52.97% | ― | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
46 Neutral | $302.72M | ― | -71.87% | ― | -15.14% | 15.84% | |
45 Neutral | $675.96M | ― | -238.46% | ― | 71.17% | 23.89% | |
42 Neutral | $38.57M | ― | -270.20% | ― | 144.50% | -141.91% | |
42 Neutral | $100.68M | ― | -76.26% | ― | -72.22% | 51.95% | |
39 Underperform | $962.71M | ― | -54.00% | ― | 59.55% | 3.09% |
* Healthcare Sector Average
Performance Comparison
RGNX
RegenXBio
6.55
-15.30
-70.02%
SRPT
Sarepta Therapeutics
98.37
-25.39
-20.52%
BLUE
Bluebird Bio
3.73
-22.87
-85.98%
QURE
uniQure
13.78
8.96
185.89%
NTLA
Intellia Therapeutics
9.22
-18.30
-66.50%
ADVM
Adverum Biotechnologies
4.50
-12.80
-73.99%
RegenXBio Earnings Call Summary
Earnings Call Date: Mar 13, 2025 | % Change Since: 0.00% | Next Earnings Date: Apr 30, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant advancements in REGENXBIO's gene therapy programs with upcoming milestones, indicating strong progress in the pipeline. However, there were decreases in R&D expenses and cash, reflecting some financial challenges.Highlights
Advancements in Gene Therapy Programs
REGENXBIO has made significant progress in several gene therapy programs, including RGX-202 for Duchenne, RGX-121 for MPS II, and RGX-314 for wet AMD and DR. Key milestones include the initiation of BLA filing for RGX-121 and upcoming pivotal trials.
First Functional Data for Duchenne Program
The company expects to share the first functional data from the Duchenne program later this month, marking a significant step in its development.
Strong Financial Position
REGENXBIO ended the quarter with $279 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2026.
Positive Data from Retinal Studies
RGX-314 for wet AMD showed a 97% reduction in treatment burden at 9 months, with 100% of patients needing 0 or 1 supplemental injections.
Lowlights
Decreased R&D Expenses
R&D expenses decreased from $58 million in Q3 2023 to $54 million in Q3 2024, primarily due to decreases in headcount and preclinical activities.
Cash Decrease
The company's cash position decreased from $314 million as of December 31, 2023, to $279 million as of September 30, 2024, despite raising $131 million from a public offering.
Company Guidance
During the Q3 2024 earnings call for REGENXBIO, several key metrics and guidance were provided. The company reported cash, cash equivalents, and marketable securities totaling $279 million as of September 30, 2024, with expectations to fund operations into 2026. Research and development expenses for the quarter were $54 million, down from $58 million in the same period the previous year. The guidance highlighted several upcoming milestones, including the initiation of a pivotal trial for RGX-202, expected to begin imminently, and the completion of the End-of-Phase II meeting with the FDA for RGX-314 in diabetic retinopathy within Q4 2024. Additionally, the first module of a rolling BLA for RGX-121 was submitted as planned, with completion anticipated in Q1 2025. The company also pointed out potential financial impacts not included in their guidance, such as payments from AbbVie for milestone achievements and the potential monetization of a Priority Review Voucher for RGX-121.RegenXBio Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
RegenXBio Partners with Nippon Shinyaku on Gene Therapies
Positive
Jan 14, 2025
On January 14, 2025, REGENXBIO Inc. announced a strategic collaboration with Nippon Shinyaku Co., Ltd. to develop and commercialize RGX-121 and RGX-111, aimed at treating Mucopolysaccharidosis II and I respectively. The agreement involves REGENXBIO receiving an upfront payment of $110 million and potential milestone payments totaling up to $700 million, along with significant royalties. REGENXBIO will lead the manufacturing of these gene therapies, while Nippon Shinyaku will handle their commercialization in the U.S. and Asia. This partnership is expected to enhance both companies’ positions in the gene therapy market, offering potentially transformative treatments for these rare diseases.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.